Tarsus to Participate in Upcoming Investor Conference

Tarsus (NASDAQ:TARS) management will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Tuesday, November 11, 2025 at 11:30 a.m. PT / 2:30 p.m. ET.

Rhea-AI Summary

Tarsus (NASDAQ:TARS) management will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on Tuesday, November 11, 2025 at 11:30 a.m. PT / 2:30 p.m. ET. A live webcast will be available and replays will be posted on the company's events page within 48 hours and archived for a limited time.

Argus Nov 6 session

-0.16% close to close Open Argus

Details

News Market Reaction – TARS

On Nov 6, the first trading day after this news, TARS closed 0.16% below the previous close.

Data tracked by StockTitan Argus for the Nov 6 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2^nd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 11^th, at 11:30 a.m. PT / 2:30 p.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.

Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tarsus (TARS) present at the Guggenheim Healthcare Innovation Conference?

Tarsus management will present on Tuesday, November 11, 2025 at 11:30 a.m. PT / 2:30 p.m. ET.

How can investors watch the Tarsus (TARS) fireside chat on November 11, 2025?

A live webcast will be available and can be accessed via the events section on the Tarsus website.

Will a replay of the Tarsus (TARS) Guggenheim presentation be available?

Yes. Replays will be posted on the Tarsus website within 48 hours and archived for a limited time.

Where on the Tarsus website can I find the webcast and replay for the November 11, 2025 event?

The webcast and replay will be available in the events section of the Tarsus investor website.

What time is the Tarsus (TARS) presentation in Eastern Time on November 11, 2025?

The fireside chat is scheduled for 2:30 p.m. ET on November 11, 2025.

How long will the replay of the Tarsus (TARS) Guggenheim presentation be archived?

The replay will be archived on the Tarsus website for a limited time; no specific duration was provided.